Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Centene
CNC
|
+$440M |
| 2 |
IQVIA
IQV
|
+$269M |
| 3 |
AGN
Allergan plc
AGN
|
+$247M |
| 4 |
General Dynamics
GD
|
+$183M |
| 5 |
Fidelity National Information Services
FIS
|
+$158M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$793M |
| 2 |
MDCO
Medicines Co
MDCO
|
+$282M |
| 3 |
ZAYO
Zayo Group Holdings, Inc.
ZAYO
|
+$236M |
| 4 |
S&P Global
SPGI
|
+$175M |
| 5 |
MYOK
MyoKardia, Inc. Common Stock
MYOK
|
+$104M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.14% |
| 2 | Communication Services | 12.39% |
| 3 | Technology | 10.92% |
| 4 | Industrials | 5.44% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Alnylam Pharmaceuticals
ALNY
$31.6B
| $163M | 1.4% |
1,500,000
+50,000
| +3% | +$5.77M |
|
27
Palo Alto Networks
PANW
$292B
| $162M | 1.39% |
5,920,326
-730,170
| -11% | -$25.5M |
|
28
Ascendis Pharma A/S
ASND
$16.6B
| $155M | 1.33% |
1,376,349
+97,349
| +8% | +$12.6M |
|
29
TransUnion
TRU
$16.2B
| $134M | 1.15% |
2,023,887
+496,116
| +32% | +$42.8M |
|
|
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| $134M | 1.15% |
35,200,000
+4,825,050
| +16% | +$15.9M |
|
31
Qiagen
QGEN
$9.1B
| $123M | 1.06% |
2,792,374
+761,032
| +37% | +$29.7M |
|
|
FTSV
32
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $105M | 0.91% |
+1,105,000
| New | +$66.8M |
|
33
Enanta Pharmaceuticals
ENTA
$392M
| $90M | 0.77% |
1,750,000
| – | – |
|
|
RARX
34
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $69.1M | 0.59% |
1,440,000
+251,900
| +21% | +$11.7M |
|
35
Fate Therapeutics
FATE
$279M
| $66.6M | 0.57% |
3,000,000
+750,000
| +33% | +$19M |
|
|
WMGI
36
DELISTED
Wright Medical Group Inc
WMGI
| $65.2M | 0.56% |
2,275,000
+1,585,000
| +230% | +$47M |
|
|
GRFS
37
Grifois
GRFS
$5.44B
| $62.7M | 0.54% |
3,113,222
| – | – |
|
38
Zymeworks
ZYME
$2.05B
| $62.1M | 0.53% |
1,750,000
+50,000
| +3% | +$2.05M |
|
|
ZGNX
39
DELISTED
Zogenix, Inc.
ZGNX
| $55.6M | 0.48% |
2,250,000
+500,000
| +29% | +$18.2M |
|
|
KYNB
40
Kyntra Bio
KYNB
$30.4M
| $55.6M | 0.48% |
63,987
+9,987
| +18% | +$9.93M |
|
|
BRMK
41
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
| $53.9M | 0.46% |
7,170,213
-4,400
| -0.1% | -$48.5K |
|
|
APLS
42
DELISTED
Apellis Pharmaceuticals
APLS
| $53.6M | 0.46% |
2,000,000
+1,500,000
| +300% | +$53.3M |
|
|
PLYA
43
DELISTED
Playa Hotels & Resorts
PLYA
| $53.6M | 0.46% |
30,606,930
| – | – |
|
|
MRTX
44
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $46.1M | 0.4% |
600,000
+425,000
| +243% | +$38.1M |
|
45
Equifax
EFX
$22.6B
| $45.2M | 0.39% |
378,275
-273,914
| -42% | -$39.8M |
|
46
Agios Pharmaceuticals
AGIO
$1.98B
| $44.4M | 0.38% |
1,250,000
| – | – |
|
|
DCPH
47
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $41.2M | 0.35% |
1,000,000
+50,000
| +5% | +$2.78M |
|
|
KRTX
48
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $40.8M | 0.35% |
567,047
-32,953
| -5% | -$2.82M |
|
49
United Therapeutics
UTHR
$22B
| $34.6M | 0.3% |
+365,000
| New | +$34.7M |
|
50
Sarepta Therapeutics
SRPT
$1.98B
| $34.2M | 0.29% |
+350,000
| New | +$40M |
|
Similar funds
Thomas Steyer's Q1 2020 Portfolio in Review
As of Q1 2020, Thomas Steyer held 136 positions worth $11.7B, down 21% from $14.8B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Thomas Steyer withdrew a net $1.15B in Q1 2020, closing 34 positions and reducing 23 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $793M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 47% a quarter earlier, followed by Communication Services and Technology.
Against the trend, Thomas Steyer opened a new position in Centene worth $431M.
- Thomas Steyer's largest Q1 2020 buy was Centene: 7,250,000 shares worth $431M.
- Thomas Steyer added most to IQVIA in Q1 2020, an estimated $269M increase.
- Thomas Steyer's biggest Q1 2020 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $104M.
- Thomas Steyer fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $793M.
- Thomas Steyer's ten largest holdings make up 46% of its $11.7B portfolio in Q1 2020.
- Thomas Steyer opened 17 new positions and closed 34 in Q1 2020.
- Thomas Steyer's portfolio value fell 21% quarter-over-quarter to $11.7B.
Based on Farallon Capital Management's 13F filing for Q1 2020, filed 15 May 2020.